The incidence of rheumatic immune-related adverse events (IRAEs) resulting from treatment with immune checkpoint inhibitors (ICI) remains unclear, but significant.
Why this matters
Physicians should be aware of the potential for rheumatoid side effects of ICI treatment.
Prevalence, clinical characteristics, and treatment data were extracted and summarized from studies that reported musculoskeletal and rheumatic IRAEs with ICI treatment.
Funding: Not indicated.
52 studies with original data on ICI treatment and information about musculoskeletal or rheumatic IRAEs were selected, including 33 clinical trials, 3 observational studies, and 16 series or case reports.